Jupiter Neurosciences Registers 16M Shares for Yorkville Resale
Jupiter Neurosciences, Inc. has filed an S-1 registration statement to register an additional 16,000,000 common shares for resale by Yorkville, its selling stockholder. These shares are part of a Standby Equity Purchase Agreement (SEPA) under which the company may receive up to $17.2 million from future sales to Yorkville, in addition to $2.8 million already received. The financing arrangement also includes $6.0 million in Pre-Paid Advances from Yorkville in exchange for Convertible Notes, which carry an 8% annual interest rate and mature on October 24, 2026. Proceeds from these sales are intended to support the company's Phase 2 trial for Parkinson's Disease and accelerate marketing for its Nugevia product line.
Key Highlights
- Registers 16,000,000 common shares for resale by Yorkville.
- Shares issued under Standby Equity Purchase Agreement (SEPA).
- Company may receive up to $17.2 million from future SEPA sales.
- Already received $2.8 million from prior SEPA sales to Yorkville.
- Yorkville provided $6.0 million in Pre-Paid Advances for Convertible Notes.
- Convertible Notes carry 8% interest, mature October 24, 2026.
- Stockholders approved share issuance exceeding Nasdaq 19.99% cap.
- Proceeds to fund Parkinson's Phase 2 trial and Nugevia marketing.
Price Impact
More from JUNS
Jupiter Neurosciences to Vote on Reverse Split, Equity Plan, Directors
Jupiter Neurosciences Director Allison Brady Resigns
Jupiter Neurosciences Promotes Alison Silva to COO & President; Boosts Salary & Grants Options